• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Relatlimab and nivolumab provide greater survival benefit for advanced melanoma

byDavid XiangandHarsh Shah
January 17, 2022
in Chronic Disease, Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with untreated metastatic or unresectable melanoma, the combination of Relatlimab and Nivolumab was associated with greater progression-free survival than Nivolumab alone.

2. In patients with advanced melanoma, treatment with Relatlimab and Nivolumab demonstrated no new safety signals than Nivolumab alone.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Immunotherapy with PD-1 inhibitors (Nivolumab) and LAG-3 inhibitors (Relatlimab) have been shown to improve outcomes in patients with untreated or advanced melanoma. Relatlimab and Nivolumab have been proposed to have synergistic antitumor activity, and thus the combination of these medications has been proposed for untreated metastatic or unresectable melanoma. There is a gap in knowledge as to understanding the progression-free survival benefit of Relatlimab and Nivolumab used together. This study found that treatment with Relatlimab and Nivolumab provided a greater progression-free survival than Nivolumab alone in patients with advanced melanoma. This study was limited by the exclusion of patients with rare melanoma subtypes and patients that are typically excluded from melanoma clinical trials such as those with brain metastases. Nevertheless, these study’s findings are significant, as they demonstrate that combination therapy of Relatlimab with Nivolumab is more effective than Nivolumab alone for patients with melanoma, suggesting a new therapeutic strategy for previously untreated metastatic or unresectable melanoma.

Click to read the study in NEJM

Relevant Reading: A New Combination Immunotherapy in Advanced Melanoma

In-Depth [randomized control trial]: This randomized control trial included 714 patients; 355 in the Relatlimab-Nivolumab group and 359 in the Nivolumab only group at 111 sites in North America, Central America, South America, Europe, Australia, and New Zealand. Patients were eligible if they were older than 12 years and had confirmed unresectable stage III or IV melanoma, and were eligible even if they had previously received immunotherapies. Patients who had uveal melanoma or untreated brain or leptomeningeal metastases were excluded from the study. The primary outcome measure was progression-free survival, defined as the time between the date of randomization and the earliest date of documented disease progression or the date of death from any cause, whichever occurred first. Outcomes in the primary analysis were assessed via a two-sided log-rank test and a Cox proportional-hazards model, as well as Kaplan-Meier methods. Between the two treatment groups, Relatlimab-Nivolumab had a longer median progression-free survival of 10.1 months (95% confidence interval [CI], 6.4 to 15.7) as compared to 4.6 months with Nivolumab (95% CI, 3.4 to 5.6). Furthermore, progression-free survival at one year from treatment was higher in the Relatlimab-Nivolumab group (47.7%, 95% CI 41.8 to 53.2) as compared to Nivolumab (36.0%, 95% CI 30.5 to 41.6). The study also demonstrated that Relatlimab-Nivolumab demonstrated no new safety signals, as there were no significant differences in health-related quality of life between the treatment groups. Overall, this study determined that there was a significantly greater benefit regarding progression-free survival when using Relatlimab-Nivolumab as compared to Nivolumab alone.

RELATED REPORTS

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: melanomaNivolumabprogression-free survivalRelatlimab
Previous Post

Online Eye Movement Desensitization and Reprocessing Therapy may improve mental health

Next Post

Mass administration of three-dose azithromycin reduces community prevalence of yaws

RelatedReports

Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue
StudyGraphics

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

April 28, 2022
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
StudyGraphics

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 28, 2022
Oncology

Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 18, 2022
Next Post
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Mass administration of three-dose azithromycin reduces community prevalence of yaws

Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse

Dog training therapy may improve symptoms of post-traumatic stress disorder

#VisualAbstract: Gonadotrophin-releasing hormone analogs reduces rates of premature ovarian insufficiency  in premenopausal women with breast cancer

#VisualAbstract: Gonadotrophin-releasing hormone analogs reduces rates of premature ovarian insufficiency in premenopausal women with breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.